Data is not available at this time.
Ascom Holding AG operates in the healthcare ICT and mobile workflow solutions sector, specializing in nurse call systems, clinical workflow software, and mobile communication devices. The company serves acute care hospitals, long-term care facilities, and enterprise clients in retail, security, and hospitality. Its flagship products, such as teleCARE IP and Telligence, enhance patient monitoring and staff coordination, positioning Ascom as a niche player in digital healthcare workflow optimization. The firm differentiates itself through integrated solutions that bridge clinical data, communication, and workflow automation, addressing inefficiencies in care delivery. With a focus on interoperability and real-time decision support, Ascom competes against larger medical technology providers by offering specialized, modular systems tailored to mid-market healthcare providers. Its consulting and support services further strengthen customer retention and recurring revenue streams.
Ascom reported CHF 286.7 million in revenue for FY 2024, with net income of CHF 3.7 million, reflecting modest profitability in a competitive landscape. Operating cash flow of CHF 20 million indicates healthy liquidity generation, though capital expenditures of CHF 4.4 million suggest restrained reinvestment. The diluted EPS of CHF 0.1 underscores lean earnings relative to its market cap.
The company’s ability to convert revenue into operating cash flow (7% of revenue) demonstrates operational efficiency, albeit with limited earnings scalability. Zero debt enhances financial flexibility, but the absence of leverage may indicate conservative growth strategies. The beta of 1.12 suggests moderate sensitivity to market volatility.
Ascom maintains a solid balance sheet with CHF 18.6 million in cash and no debt, providing a robust liquidity position. The lack of leverage reduces financial risk, though it may limit capital-intensive expansion. Shareholders’ equity appears stable, supported by consistent, if unspectacular, profitability.
Growth appears tempered, with a CHF 0.1 per share dividend reflecting a cautious capital return policy. The company’s focus on healthcare digitization offers long-term tailwinds, but near-term revenue expansion may depend on adoption rates of its workflow solutions in target markets.
At a market cap of CHF 117.6 million, Ascom trades at a revenue multiple of approximately 0.4x, indicating modest market expectations. The beta-adjusted profile suggests investors price in sector-specific risks alongside growth potential in healthcare ICT.
Ascom’s integrated workflow solutions and debt-free structure provide a foundation for steady growth, though scalability remains a challenge. The healthcare sector’s increasing reliance on digital tools positions the company favorably, but execution and competitive pressures will dictate future performance.
Company filings, London Stock Exchange data
show cash flow forecast
| Fiscal year | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | |
INCOME STATEMENT | ||||||||||||||||||||||||||
| Revenue growth rate, % | NaN | |||||||||||||||||||||||||
| Revenue, $ | NaN | |||||||||||||||||||||||||
| Variable operating expenses, $m | NaN | |||||||||||||||||||||||||
| Fixed operating expenses, $m | NaN | |||||||||||||||||||||||||
| Total operating expenses, $m | NaN | |||||||||||||||||||||||||
| Operating income, $m | NaN | |||||||||||||||||||||||||
| EBITDA, $m | NaN | |||||||||||||||||||||||||
| Interest expense (income), $m | NaN | |||||||||||||||||||||||||
| Earnings before tax, $m | NaN | |||||||||||||||||||||||||
| Tax expense, $m | NaN | |||||||||||||||||||||||||
| Net income, $m | NaN | |||||||||||||||||||||||||
BALANCE SHEET | ||||||||||||||||||||||||||
| Cash and short-term investments, $m | NaN | |||||||||||||||||||||||||
| Total assets, $m | NaN | |||||||||||||||||||||||||
| Adjusted assets (=assets-cash), $m | NaN | |||||||||||||||||||||||||
| Average production assets, $m | NaN | |||||||||||||||||||||||||
| Working capital, $m | NaN | |||||||||||||||||||||||||
| Total debt, $m | NaN | |||||||||||||||||||||||||
| Total liabilities, $m | NaN | |||||||||||||||||||||||||
| Total equity, $m | NaN | |||||||||||||||||||||||||
| Debt-to-equity ratio | NaN | |||||||||||||||||||||||||
| Adjusted equity ratio | NaN | |||||||||||||||||||||||||
CASH FLOW | ||||||||||||||||||||||||||
| Net income, $m | NaN | |||||||||||||||||||||||||
| Depreciation, amort., depletion, $m | NaN | |||||||||||||||||||||||||
| Funds from operations, $m | NaN | |||||||||||||||||||||||||
| Change in working capital, $m | NaN | |||||||||||||||||||||||||
| Cash from operations, $m | NaN | |||||||||||||||||||||||||
| Maintenance CAPEX, $m | NaN | |||||||||||||||||||||||||
| New CAPEX, $m | NaN | |||||||||||||||||||||||||
| Total CAPEX, $m | NaN | |||||||||||||||||||||||||
| Free cash flow, $m | NaN | |||||||||||||||||||||||||
| Issuance/(repurchase) of shares, $m | NaN | |||||||||||||||||||||||||
| Retained Cash Flow, $m | NaN | |||||||||||||||||||||||||
| Pot'l extraordinary dividend, $m | NaN | |||||||||||||||||||||||||
| Cash available for distribution, $m | NaN | |||||||||||||||||||||||||
| Discount rate, % | NaN | |||||||||||||||||||||||||
| PV of cash for distribution, $m | NaN | |||||||||||||||||||||||||
| Current shareholders' claim on cash, % | NaN |